Boryeong, 3Q Sales 208.3 Billion KRW... Operating Profit Up 11%

Boryung announced on the 25th that its provisional consolidated operating results for the third quarter recorded sales of 208.317 billion KRW and operating profit of 18.458 billion KRW. Compared to the same period last year, sales increased by 5.3% and operating profit rose by 11.1%.

Boryeong Headquarters Exterior
[Photo by Boryeong]

The company stated, "We continue to achieve quarterly sales in the 200 billion KRW range," and explained, "We have laid the foundation for future sales growth." Regarding operating profit, they added, "We expect a double-digit operating margin going forward," and "We are continuously expanding the proportion of self-produced products to secure profitability."

By business segment, the growth in the prescription drug sector was remarkable. Prescription drugs recorded sales of 173.5 billion KRW, showing a 7% increase compared to the same period last year. In particular, in the oncology field, the LBA brand 'Gemza' is performing well, and in the oncology supportive care area, 'Onbeveji' and 'Gracin' achieved sales growth, increasing sales by 13.9 billion KRW compared to the same period last year.

On a cumulative basis for the third quarter, sales amounted to 628.388 billion KRW and operating profit to 53.492 billion KRW. Compared to the same period last year, sales grew by 12.4% and operating profit by 12.8%. It is expected that Boryung will easily achieve its targets for this year of 810 billion KRW in sales and 61 billion KRW in operating profit.

This content was produced with the assistance of AI translation services.